

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM853723

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Trademark Security Interests Recorded at Reel 6133, Frame 0347		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Deutsche Bank AG New York Branch, as Collateral Agent		11/14/2023	Banking Corporation: GERMANY
RECEIVING PARTY DATA			
Name:	Mallinckrodt Hospital Products IP Limited		
Street Address:	College Business & Technology Park Cruiserath, Blanchardstown		
City:	Dublin		
State/Country:	IRELAND		
Postal Code:	15		
Entity Type:	Private Limited Company: IRELAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	87163067	ONSTORVIS	
Serial Number:	86532781	TERLIVAZ TERLIPRESSIN FOR INJECTION	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2136207848		
Email:	iprecordations@whitecase.com		
Correspondent Name:	Justine Lu/White & Case LLP		
Address Line 1:	555 South Flower Street, Suite 2700		
Address Line 4:	Los Angeles, CALIFORNIA 90071		
ATTORNEY DOCKET NUMBER:	1111779-3049-S216		
NAME OF SUBMITTER:	Justine Lu		
SIGNATURE:	/Justine Lu/		
DATE SIGNED:	11/15/2023		
Total Attachments: 4			
source=MNK - Trademark Release (2014 CA - 0347) (Executed)#page1.tif			
source=MNK - Trademark Release (2014 CA - 0347) (Executed)#page2.tif			

CH \$65.00 87163067

source=MNK - Trademark Release (2014 CA - 0347) (Executed)#page3.tif

source=MNK - Trademark Release (2014 CA - 0347) (Executed)#page4.tif

RELEASE OF TRADEMARK SECURITY INTERESTS, dated as of November 14, 2023 (this “Release”), by Deutsche Bank AG New York Branch, as collateral agent under the Credit Agreement (as defined below) (in such capacity, the “Collateral Agent”) in favor of **MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED**, an Ireland private limited company with an address at College Business & Technology Park Cruiserath, Blanchardstown, Dublin 15, Ireland (the “Pledgor”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the U.S. Collateral Agreement, referred to below.

A. Reference is made to (i) the U.S. Collateral Agreement, dated as of March 19, 2014 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “U.S. Collateral Agreement”), among MALLINCKRODT INTERNATIONAL FINANCE S.A., a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (R.C.S Luxembourg) under number B 172.865 (the “Lux Borrower”), MALLINCKRODT CB LLC, a Delaware limited liability company (the “Co-Borrower”, and together with the Lux Borrower, the “Borrowers”), Mallinckrodt Finance GmbH (the “Swiss Finco”), each other Subsidiary Loan Party listed on the signature pages thereof and each other Subsidiary Loan Party that becomes a party thereto after the Closing Date (as defined therein) and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the “Collateral Agent”) for the Secured Parties (as defined therein) and (ii) the Notice of Grant of Security Interest in Trademarks, dated as of August 17, 2017, among the Pledgors party thereto and the Collateral Agent (such documents set forth in clauses (i) and (ii) the “Security Documents”).

B. Pursuant to the Security Documents, the Pledgor granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all right, title and interest of the Pledgor in, to and under, among other things, the Trademarks of the Pledgor, including those set forth on Schedule I hereto (collectively, the “Trademark Collateral”), which security interest was recorded with the United States Patent and Trademark Office on August 18, 2017 at Reel/Frame 6133/0347.

Accordingly, for good and valuable consideration, the receipt and sufficiency of the which are hereby acknowledged, in accordance with the U.S. Collateral Agreement, the Collateral Agent does hereby release, relinquish and discharge any and all security interests it has against the Trademark Collateral. If and to the extent that the Collateral Agent has acquired any right, title or interest in and to the Trademark Collateral, the Collateral Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the Pledgor. The Collateral Agent acknowledges and agrees that the Issuers or their designees shall, on behalf of the Collateral Agent (at the Issuers’ sole cost and expenses), make filings, including of this Release, with the United States Patent and Trademark Office and other necessary filings to evidence the release and termination of the Collateral Agent’s security interests in the Trademark Collateral. The Collateral Agent agrees to take all further actions, and provide to the Pledgor and its successors, assigns or other legal representatives, all such cooperation and


assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Pledgor, at the Pledgor's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.


THIS RELEASE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE COLLATERAL AGENT'S REPRESENTATIVES, SUCCESSORS, ASSIGNS AND TRANSFEREES.

[The remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

DEUTSCHE BANK AG NEW YORK BRANCH,
as Collateral Agent

By: 
Name: Philip Tancorra
Title: Director

By: 
Name: Lauren Danbury
Title: Vice President

[SIGNATURE PAGE TO RELEASE OF TRADEMARK SECURITY INTERESTS]

Schedule I
Trademarks

1	Serial #: <u>86532781</u> Filing Dt: 02/12/2015 Reg #: NONE Reg. Dt: Mark: TERLIVAZ TERLIPRESSIN FOR INJECTION
2	Serial #: <u>87163067</u> Filing Dt: 09/07/2016 Reg #: NONE Reg. Dt: Mark: ONSTORVIS